ETPharma
69.5K subscribers
Verified ChannelAbout ETPharma
A Single Portal for All-Inclusive Pharma News Coverage | ETPharma.com
Similar Channels
Swipe to see more
Posts
Zydus plans to commercialise the formulation in other emerging markets as well and is actively exploring licensing opportunities with partners for it. Read more: https://pharma.economictimes.indiatimes.com/news/pharma-industry/zydus-lifesciences-develops-unique-single-pen-device-for-semaglutide-dosing/121348607
Induction of labor was also associated with a lower likelihood of cesarean delivery and fewer maternal complications, researchers reported in The Lancet. Read more: https://pharma.economictimes.indiatimes.com/news/research-and-development/researchers-identify-best-drugs-for-severe-covid/121363914
On risk-based inspections, it said that while implementing the Schedule-M, "no risk-based inspection should be undertaken, except on critical issues, till December 2026, and thereafter in case of further extension," the letter said. Read more: https://pharma.economictimes.indiatimes.com/news/pharma-industry/msme-pharma-body-calls-for-waiver-of-risk-based-inspections-amid-upgrade/121372251
Under the new FDA leadership, COVID vaccine makers are seeing greater regulatory scrutiny and facing tighter requirements for their shots that could increase their expenses. Read more: https://pharma.economictimes.indiatimes.com/news/pharma-industry/moderna-seeks-fda-approval-for-updated-covid-vaccine-targeting-dominant-strain/121372219
Eylea, an injection against the leading causes of blindness among the elderly, is currently approved in the EU for treatment intervals of up to five months. Bayer has developed it jointly with Regeneron. Read more: https://pharma.economictimes.indiatimes.com/news/pharma-industry/bayer-secures-eu-approval-for-longer-eylea-treatment-intervals-against-blindness/121360513
Pharmazz Inc is a biopharmaceutical company, developing two leading drug candidates, Sovateltide for treatment of acute cerebral ischemic stroke and Centhaquine for treatment of hypovolemic shock. Read more: https://pharma.economictimes.indiatimes.com/news/pharma-industry/sun-pharma-boosts-investment-in-pharmazz-inc-to-25-million-expands-stake-to-227/121372261
Venus Remedies already has a robust presence in 32 PIC/S countries, including South Africa, Thailand, Malaysia, Saudi Arabia, and Australia, with plans for continued expansion, it said. Read more: https://pharma.economictimes.indiatimes.com/news/pharma-industry/venus-remedies-gets-ukrainian-gmp-renewal-certification/121379733
During the period, the European business reported maximum growth of 20 per cent to ₹733 crore, while India sales rose marginally by 0.4 per cent, held back by weak growth in the acute respiratory segment and a 10 per cent decline in diabetes market value due to new generic launches. Read more: https://pharma.economictimes.indiatimes.com/news/financial-performance/glenmark-pharmaceuticals-achieves-63-revenue-growth-in-q4-driven-by-strong-european-performance/121381939
While the company’s formulation sales in India, Emerging markets and Rest of the world reported an expansion, the US formulation sales reported a YoY decline of 2.5 per cent to $464 million (around ₹3,940 crore) Read more: https://pharma.economictimes.indiatimes.com/news/financial-performance/sun-pharma-reports-q4-revenue-growth-despite-declining-us-sales/121350257
When he stepped down as CEO in 2016, Novo cited as reasons increased competition in the U.S. market and pricing pressures for insulin, then its most profitable line. Read more: https://pharma.economictimes.indiatimes.com/news/pharma-industry/novo-nordisks-ceo-shake-up-former-chief-lars-rebien-sorensen-returns-to-influence-leadership-transition/121348649